A Rhodopsin Transport Assay by High-Content Imaging Analysis

Area of Science:

• Genetics and Molecular Biology
• Ophthalmology
• Pharmacology

Background:

• Autosomal dominant retinitis pigmentosa (RP) is a progressive blinding disease caused by rhodopsin misfolding mutations.
• Misfolded rhodopsin accumulates in the endoplasmic reticulum (ER), leading to rod photoreceptor cell death.
• Current treatments for RP are limited, necessitating novel therapeutic strategies.

Purpose of the Study:

• To investigate the potential of pharmacological chaperones to alleviate the cytotoxicity of misfolded rhodopsin mutants.
• To identify compounds that stabilize mutant rhodopsin and restore its proper transport.
• To develop and validate a high-content imaging assay for evaluating compound efficacy against various rhodopsin mutants.

Main Methods:

• Utilized immunostaining and high-content imaging analysis to quantify mutant rhodopsin levels in cells and on the plasma membrane.
• Applied a previously established luminescence-based high-throughput screen (HTS) to identify initial chaperone candidates.
• Tested 11 compounds against six different RP-associated rhodopsin mutants to assess their pharmacological profiles.

Main Results:

• The high-content imaging assay effectively distinguished true hits from false positives identified in the HTS.
• Quantified multiple parameters to evaluate compound efficacy and understand mutant rhodopsin structural stability.
• Generated 2-D pharmacological profiles for compounds and rhodopsin mutants, providing insights into treatment potential.

Conclusions:

• Pharmacological stabilization of misfolded rhodopsin is a viable strategy for treating autosomal dominant retinitis pigmentosa.
• High-content imaging analysis is a powerful tool for validating HTS results and characterizing compound effects.
• This approach offers a promising avenue for developing effective therapies for RP by targeting protein misfolding.